Home » Stocks » ALPN

Alpine Immune Sciences, Inc. (ALPN)

Stock Price: $12.00 USD 0.20 (1.69%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 283.18M
Revenue (ttm) 9.34M
Net Income (ttm) -27.94M
Shares Out 20.83M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $12.00
Previous Close $11.80
Change ($) 0.20
Change (%) 1.69%
Day's Open 11.69
Day's Range 11.69 - 12.22
Day's Volume 79,999
52-Week Range 2.58 - 16.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting

1 week ago - Business Wire

Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I

3 weeks ago - Business Wire

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 0.00% and 101.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

1 month ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences

2 months ago - Business Wire

Although micro-cap stocks don't perform well during an economic downturn, they outperform the market during periods of recovery. Here are 7 stocks to invest in as we head toward a new normal.

Other stocks mentioned: CELH, PI, UPWK, WTRH, YELP, ZUO
4 months ago - InvestorPlace

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Executive Leadership Addition and Promotion

4 months ago - Business Wire

Alpine Immune Sciences is a stellar growth bio-stock that is reaching a point of growth inflection. Back in June last year, Alpine secured a highly favorable partnership with AbbVie.

4 months ago - Seeking Alpha

Innovation paid off big for investors.

Other stocks mentioned: AQB, CTIC, IBIO
4 months ago - The Motley Fool

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference

4 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

4 months ago - Business Wire

Alpine (ALPN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

5 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

5 months ago - Business Wire

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

5 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update

6 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

7 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

7 months ago - Business Wire

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

8 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

9 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update

9 months ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces $60 Million Private Placement

9 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).

9 months ago - Zacks Investment Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ATNM, PCRX, TBIO
10 months ago - Zacks Investment Research

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

Other stocks mentioned: CNCE, MRAM, PIXY, SGBX
10 months ago - Forbes

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

10 months ago - Zacks Investment Research

Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug.

10 months ago - GeekWire

Shares of the micro-cap, clinical-stage immune therapy company Alpine Immune Sciences Inc (NASDAQ: ALPN) were advancing strongly Thursday.

10 months ago - Benzinga

Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc.

10 months ago - 24/7 Wall Street

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.

10 months ago - Zacks Investment Research

Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Alpine Immune Sciences, Inc. (ALPN) CEO.

1 year ago - Seeking Alpha

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016.

Other stocks mentioned: BEN, CMS, D, KSS
2 years ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.

2 years ago - Zacks Investment Research

Alpine Immune Sciences: A New Name On The Radar

2 years ago - Seeking Alpha

About ALPN

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B ... [Read more...]

Industry
Biotechnology
CEO
Mitchell Gold
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
ALPN
Full Company Profile

Financial Performance

In 2020, ALPN's revenue was $9.34 million, an increase of 436.49% compared to the previous year's $1.74 million. Losses were -$27.94 million, -33.24% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ALPN stock is "Strong Buy." The 12-month stock price forecast is 21.40, which is an increase of 78.33% from the latest price.

Price Target
$21.40
(78.33% upside)
Analyst Consensus: Strong Buy